Company Description
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines.
It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context.
The company’s lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care.
It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer.
The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.
| Country | Canada |
| Founded | 1994 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Neil Maresky |
Contact Details
Address: 121 Richmond Street West, Penthouse Suite, 1300 Toronto, ON M5H2K1 Canada | |
| Phone | 416-346-7764 |
| Website | psyencebiomed.com |
Stock Details
| Ticker Symbol | PBM |
| Exchange | NASDAQ |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0001985062 |
| ISIN Number | CA74449F1009 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Neil Maresky M.D. | Chief Executive Officer and Director |
| Jody Aufrichtig | Co-Founder, Executive Chairman and Strategic Business Development Officer |
| Warwick Ron Corden-Lloyd | Chief Financial Officer |
| Taryn Vos | General Counsel |
| Mary-Elizabeth Gifford | Chief of Global Impact |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | 6-K | Report of foreign issuer |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | 424B3 | Prospectus |
| Nov 8, 2024 | EFFECT | Notice of Effectiveness |
| Nov 1, 2024 | 6-K | Report of foreign issuer |
| Oct 30, 2024 | F-1 | Registration statement for certain foreign private issuers |
| Oct 23, 2024 | 6-K | Report of foreign issuer |
| Oct 10, 2024 | EFFECT | Notice of Effectiveness |